Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 868-871, February 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pharoah, P. D. P.
Right arrow Articles by Ponder, B. A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pharoah, P. D. P.
Right arrow Articles by Ponder, B. A. J.
[Cancer Research 59, 868-871, February 15, 1999]
© 1999 American Association for Cancer Research

Epidemiology and Prevention

Survival in Familial, BRCA1-associated, and BRCA2-associated EpithelialOvarian Cancer1

Paul D. P. Pharoah2, Douglas F. Easton, Diane L. Stockton, Simon Gayther, Bruce A. J. Ponder and the United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group3

Cancer Research Campaign Human Cancer Genetics Research Group, Department of Oncology [P. D. P. P., S. G., B. A. J. P.], and Cancer Research Campaign Genetic Epidemiology Unit, Department of Community Medicine [P. D. P. P., D. F. E.], University of Cambridge Strangeways Research Laboratories, Wort’s Causeway, Cambridge, CB1 8RN; and East Anglian Cancer Intelligence Unit, Department of Community Medicine, Institute of Public Health, Cambridge [D. L. S.], CB1 2SR, United Kingdom

The natural history of hereditary and BRCA1- and BRCA2-associated epithelial ovarian cancer may differ from that of sporadic disease. The purpose of this study was to compare the clinical characteristics of BRCA1- and BRCA2-associated hereditary ovarian cancer, hereditary ovarian cancer with no identified BRCA1/2 mutation, and ovarian cancer in population-based controls. BRCA1 and BRCA2 mutation testing was carried out on index cases from 119 families with site-specific epithelial ovarian cancer or breast-ovarian cancer. We estimated overall survival in 151 patients from 57 BRCA1 and BRCA2 mutation families and compared it with that in 119 patients from 62 families in which a BRCA1/2 mutation was not identified. We compared clinical outcome and data on tumor histopathology, grade, and stage. We also compared survival in familial epithelial ovarian cancer, whether or not a mutation was identified, with that of an age-matched set of population control cases. Overall survival at 5 years was 21% (95% confidence interval, 14–28) in cases from BRCA1 mutation families, 25% (8–42) in BRCA2 mutation families, and 19% (12–26) in families with no identified mutation (P = 0.91). Survival in familial ovarian cancer cases as a whole was significantly worse than for population controls (P = 0.005). In the familial cases, we found no differences in histopathological type, grade, or stage according to mutation status. Compared to population control cases, mucinous tumors occurred less frequently in the familial cases (2 versus 12%, P < 0.001), and a greater proportion of the familial cases presented with advanced disease (83% stage III/IV versus 56%; P = 0.001). We have shown that survival in familial ovarian cancer cases is worse than that in sporadic cases, whether or not a BRCA1/2 mutation was identified, perhaps reflecting a difference in biology analogous to that observed in breast cancer.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. Soegaard, S. K. Kjaer, M. Cox, E. Wozniak, E. Hogdall, C. Hogdall, J. Blaakaer, I. J. Jacobs, S. A. Gayther, and S. J. Ramus
BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark
Clin. Cancer Res., June 15, 2008; 14(12): 3761 - 3767.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman, and S. Sadetzki
Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer
J. Clin. Oncol., January 1, 2008; 26(1): 20 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
I. Cass, C. Holschneider, N. Datta, D. Barbuto, A. E. Walts, and B. Y. Karlan
BRCA-Mutation-Associated Fallopian Tube Carcinoma: A Distinct Clinical Phenotype?
Obstet. Gynecol., December 1, 2005; 106(6): 1327 - 1334.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. M. Sowter and A. Ashworth
BRCA1 and BRCA2 as ovarian cancer susceptibility genes
Carcinogenesis, October 1, 2005; 26(10): 1651 - 1656.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. R. Lakhani, S. Manek, F. Penault-Llorca, A. Flanagan, L. Arnout, S. Merrett, L. McGuffog, D. Steele, P. Devilee, J. G. M. Klijn, et al.
Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers
Clin. Cancer Res., April 1, 2004; 10(7): 2473 - 2481.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. J. Ramus, P. D. P. Pharoah, P. Harrington, C. Pye, B. Werness, L. Bobrow, A. Ayhan, D. Wells, A. Fishman, M. Gore, et al.
BRCA1/2 Mutation Status Influences Somatic Genetic Progression in Inherited and Sporadic Epithelial Ovarian Cancer Cases
Cancer Res., January 15, 2003; 63(2): 417 - 423.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
B. C. Cooper, A. K. Sood, C. S. Davis, J. M. Ritchie, J. I. Sorosky, B. Anderson, and R. E. Buller
Preoperative CA 125 Levels: An Independent Prognostic Factor for Epithelial Ovarian Cancer
Obstet. Gynecol., July 1, 2002; 100(1): 59 - 64.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. E. Buller, M. S. Shahin, J. P. Geisler, M. Zogg, B. R. De Young, and C. S. Davis
Failure of BRCA1 Dysfunction to Alter Ovarian Cancer Survival
Clin. Cancer Res., May 1, 2002; 8(5): 1196 - 1202.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Sekine, H. Nagata, S. Tsuji, Y. Hirai, S. Fujimoto, M. Hatae, I. Kobayashi, T. Fujii, I. Nagata, K. Ushijima, et al.
Mutational Analysis of BRCA1 and BRCA2 and Clinicopathologic Analysis of Ovarian Cancer in 82 Ovarian Cancer Families: Two Common Founder Mutations of BRCA1 in Japanese Population
Clin. Cancer Res., October 1, 2001; 7(10): 3144 - 3150.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Sekine, H. Nagata, S. Tsuji, Y. Hirai, S. Fujimoto, M. Hatae, I. Kobayashi, T. Fujii, I. Nagata, K. Ushijima, et al.
Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25
Hum. Mol. Genet., June 1, 2001; 10(13): 1421 - 1429.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. E. Buller, T. A. Lallas, M. S. Shahin, A. K. Sood, M. Hatterman-Zogg, B. Anderson, J. I. Sorosky, and P. A. Kirby
The p53 Mutational Spectrum Associated with BRCA1 Mutant Ovarian Cancer
Clin. Cancer Res., April 1, 2001; 7(4): 831 - 838.
[Abstract] [Full Text]

Home page
 Am J EpidemiolHome page
V. McGuire, A. S. Whittemore, R. Norris, and I. Oakley-Girvan
Survival in Epithelial Ovarian Cancer Patients with Prior Breast Cancer
Am. J. Epidemiol., September 15, 2000; 152(6): 528 - 532.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
P.-H. Wang, W.-Y. Shyong, Y. F. Li, H.-H. Lee, W.-Y. Tsai, H.-T. Chao, C.-Y. Wu, Y.-C. Tsai, and C.-C. Yuan
BRCA1 Mutations in Taiwanese with Epithelial Ovarian Carcinoma and Sporadic Primary Serous Peritoneal Carcinoma
Jpn. J. Clin. Oncol., August 1, 2000; 30(8): 343 - 348.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. Boyd, Y. Sonoda, M. G. Federici, F. Bogomolniy, E. Rhei, D. L. Maresco, P. E. Saigo, L. A. Almadrones, R. R. Barakat, C. L. Brown, et al.
Clinicopathologic Features of BRCA-Linked and Sporadic Ovarian Cancer
JAMA, May 3, 2000; 283(17): 2260 - 2265.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.